Article History
Received: 8 September 2023
Revised: 21 September 2023
Accepted: 12 October 2023
First Online: 11 December 2023
Competing interests
: BI is a consultant for or received honoraria from Volastra Therapeutics, Johnson & Johnson/Janssen, Novartis, Eisai, AstraZeneca, and Merck, and has received research funding to Columbia University from Agenus, Alkermes, Arcus Biosciences, Checkmate Pharmaceuticals, Compugen, Immunocore, and Synthekine. The authors do not have a conflict of interest to report.